Kenvue (NYSE:KVUE) Coverage Initiated by Analysts at Evercore ISI

Evercore ISI initiated coverage on shares of Kenvue (NYSE:KVUE) in a report issued on Monday morning, MarketBeat.com reports. The firm issued an in-line rating and a $25.00 target price on the stock.

A number of other analysts also recently weighed in on KVUE. Barclays decreased their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. UBS Group cut their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Finally, Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.85.

Kenvue Stock Up 0.3 %

Shares of NYSE:KVUE opened at $23.38 on Monday. The firm has a market cap of $44.68 billion, a P/E ratio of 44.10, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue has a 12-month low of $17.67 and a 12-month high of $24.46. The business has a fifty day simple moving average of $22.13 and a 200 day simple moving average of $22.44. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Analysts predict that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were issued a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.51%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of KVUE. Norges Bank purchased a new stake in Kenvue during the fourth quarter worth about $521,348,000. Starboard Value LP bought a new stake in shares of Kenvue in the 4th quarter worth approximately $467,864,000. State Street Corp raised its holdings in shares of Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Franklin Resources Inc. lifted its stake in Kenvue by 61.5% in the fourth quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock valued at $912,059,000 after purchasing an additional 16,269,721 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its holdings in Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the period. Institutional investors own 97.64% of the company’s stock.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.